Ann: Positive Safety Data from Third Cohort of PI Clinical Trial, page-18

next 3 cohort subjects just perfunctory
making sure the trial results are incontrovertible
next group will cement , in my opinion, total non toxic safety application inside efficacy zone
the trial will carry on to find toxic emergence but likely so high a dosage to be more than safe at efficacy real life application So as to be of no concern
a major major milestone
james being rightfully coy in being more than pleased
no hurdles in sight for progress to phase 3
this will sink in soon and be explosively recognised in recce valuation prospects
no worries